The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1479
ISSUE1479
October 12, 2015
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Daclatasvir (Daklinza) for HCV Genotype 3 Infection
October 12, 2015 (Issue: 1479)
The FDA has approved daclatasvir (Daklinza – BMS),
an oral direct-acting antiviral drug, for use with
sofosbuvir (Sovaldi) for treatment of chronic hepatitis
C virus (HCV) genotype 3 infection. Daclatasvir is
the first drug approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.